Torben Jörgensen New CEO at Biotage
UPPSALA, SWEDEN. The life science company Biotage, listed on the O-list of the Stockholm stock exchange, makes a further strategic move to integrate its acquired businesses and to optimize the product portfolio, with the intention to focus on organic growth. As a part of this process, Torben Jörgensen will succeed Jeff Bork as the CEO of the company. For the last four years, Torben Jörgensen was the CEO of Affibody. Prior to that, he held similar positions at the Swedish biotech company Karo Bio, listed in Stockholm, and the Danish life science company DAKO, which annual turnover grew from DKK 230 million to DKK 820 million during Torben Jörgensen’s period as a CEO between 1990 and 1999. During this time, the global operating result rose from DKK 10 million to DKK 75 million. Torben Jörgensen will enter his duties as CEO of Biotage in conjunction with the annual general assembly on 27 April. ”Torben Jörgensen will make a valuable contribution to Biotage, and we are convinced that he is the right person to lead the company in the upcoming years when the focus will be on integration, optimization and organic growth”, said Börje Ekholm, Chairman of the Board of Biotage. Jeff Bork will continue as a board member of Biotage, with a special focus on strategic issues. During his years as a chairman and CEO of the company, Jeff Bork carried through strategic acquisitions and extensive cost reductions at Biotage, and lowered the consolidated costs in the businesses with SEK 400 million. ”Since taking on the position as the CEO of Biotage, Jeff Bork made an tremendous effort to consolidate the businesses and make the company a market leader as a distributor of medical chemical laboratories for synthesizing pharmaceutical substances. With Jeff as a board member, we can retain the continuity within the company and at the same time make use of his solid business experience”, said Börje Ekholm. For more information, please contact: Mikael Widell, +46 (0)703 11 99 60 Mikael.widell@telia.com